Skip to main content

Table 3 Study characteristics

From: Quality of life and physical activity in long-term (≥5 years post-diagnosis) colorectal cancer survivors - systematic review

First author year (ref.) country

Study design

Sample size

Age at survey

Time since diagnosisa

Cancer treatment

Cancer stage

PA instrument

QOL instrument

Meeting ACS PA guideline

Blanchard 2004 [35]

USA

Cross-sectional, population-based

86

Mean(SD)

69.22(12.5)

≥2 years 33.7%

≥5 years 30.2%

≥10 years 36.0%

Surgery

Radiation

Chemotherapy

I-IV

Adherence to ACS PA

guideline

SF-36

69.8%

Blanchard 2008 [30]b

USA

Cross-sectional, population-based

1918

Mean(SD)

70.2(11.0)

≥2 years 33.4%

≥5 years 35.3%

≥10 years 31.3%

Surgery

Radiation

Chemotherapy

Hormone therapy

Immuno therapy

BMT

I-IV

GLTEQ

SF-36

35%

Blanchard 2010 [31]b

USA

Cross-sectional, population-based

668

Mean(SD)

70.2(11.1)

≥2 years 26.8%

≥5 years 40.5%

≥10 years 32.0%

In treatment (not further specified)

I-IV

GLTEQ

SF-36

HW 20.0%

OW 30.0%

OB 24.4%

Chambers 2012 [38]

Australia

Cross-sectional & longitudinal, population-based

632

Mean

69.02

≥5 years

Mean(SD)

5(6.1)

Surgery

Chemotherapy

I-III

AAS

FACT-C

SWLS

Husson 2015 [34]c

The Netherlands

Cross-sectional & longitudinal, population-based

1739

Mean(SD)

68.4(9.4)

≥2 years

Mean(SD)

5.1(2.8)

Radiation

Chemotherapy

I-IV

EPIC

EORTC QLQ-C30

82%

Mols 2015 [9]c

The Netherlands

Cross-sectional, population-based

1648

Mean(SD)

Chemotherapy: 66.7(9.8)

No chemotherapy: 70.6(9.0)

1–11 years

Mean(SD)

Chemotherapy: 5.6(2.8)

No chemotherapy: 6.1(2.8)

Surgery

Radiation

I-IV

EPIC

EORTC QLQ-C30

CIPN20

Chemotherapy: 93%

No Chemotherapy: 89%

Rodriguez 2015 [36]

USA

Cross-sectional, population-based

593

Mean 73.8

Only ≥5 years

Mean

6.2

Number of treatments

I-III

GLTEQ

PROMIS

EQ-5D

Thraen-Borowski

2013 [37]

USA

Cross-sectional, population-based

832

Mean(SD) 81.5(5.8)

Only ≥5 years

Mean(SD)

8.2(1.7)

CHAMPS

SF-36

52%

Van Roekel 2015 [32]d

The Netherlands

Cross-sectional, mono-centric

151

Mean(SD) 69.8(8.7)

2–10 years

Mean(SD)

5.7(1.8)

Surgery

Radiation

Chemotherapy

I-III

SQUASH

EORTC QLQ-C30

WHODAS II

CIS

HADS

71%

Van Roekel 2016 [33]d

The Netherlands

Cross-sectional, mono-centric

145

Mean(SD) 70.0(8.7)

2–10 years

Mean(SD)

5.7(1.9)

Surgery

Radiation

Chemotherapy

I-III

MMOXX1

EORTC QLQ-C30

WHODAS II

CIS

HADS

  1. Ref. Reference, PA physical activity, QOL quality of life, ACS PA guideline American Cancer Society physical activity recommendations of at least 150 min of MVPA per week, SF-36 The Short Form Health Survey, BMT Bone marrow transplantation, GLTEQ Godin Leisure-Time Exercise Questionnaire, HW healty weight, OW over weight, OB obese, AAS The Active Australian Survey, FACT-C Functional Assessment of Cancer Therapy-General (FACT-G) plus CRC-specific measurements, SWLS Satisfaction With Life Scale, EPIC European Prospective Investigation into Cancer Physical Activity Questionnaire, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire, CIPN20 European Organization for Research and Treatment of Cancer QLQ-CIPN20 Chemotherapy-induced peripheral neuropathy questionnaire PROMIS Patient-Reported Outcomes Measurement Information System, EQ-5D EuroQol Five-Dimension Questionnaire, CHAMPS The Community Healthy Activities Model Program for Seniors, SQUASH The Short Questionnaire to Assess Health-enhancing physical activity, WHODAS World Health Organization Disability Assessment Schedule, CIS Checklist Individual Strength, HADS Hospital Anxiety and Depression Scale, MMOXX1 Triaxial MOX activity monitor, aTime since diagnosis at time point of QOL assessment; bArticles based on same study population: American Cancer Society’s Study of Cancer Survivors-II (SCS-II); cArticles based on same study population: All patients diagnosed between 2000 and 2009 and registered in the Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES registry); dArticles based on same study population: Energy for life after ColoRectal cancer (EnCoRe)